"The American Society of Clinical Oncology or ASCO meeting scheduled to begin on May 31st could give us a cornucopia of health care catalysts," said Jim Cramer.
Although Cramer concedes that he doesn't know exactly what will be announced at ASCO, the abstracts of the research to be presented at the conference were released last week.
"And they provide a decent sense of what's coming," he said.
The Mad Money host sifted through all the research and he concluded that a handful of companies are well worth watching as complete details of their ground breaking research are made public. They are:
Cramer will be watching for news involving a Gilead drug called Idelalisib. "It's currently in phase 3 trials as a treatment for advanced chronic lymphocytic leukemia, and it's also being studied for non-Hodgkins lymphoma," Cramer said.
Although other companies are also developing treatments, "last week, Gilead released some very positive early stage data on Idelalisib, and now the company is pushing for accelerated approval from the FDA. The overall market for these drugs could be worth $10 billion. That's a big pie," Cramer explained.
"We don't know how large Gilead's piece will be, but I think we'll get a lot more clarity once they present at the ASCO conference, and this could potentially be a needle-mover," Cramer said.